Helixmith Co

Helixmith Co ROA

The Return on Assets (ROA) of Helixmith Co (084990.KQ) as of Oct 21, 2026 is -0.30 %. In the previous year, Return on Assets (ROA) was -10.39 % — a change of -97.08% (higher).

ROA

-0.30 %

YoY

-97.08%

Last updated:

In 2025, Helixmith Co's return on assets (ROA) was -0.30 %, a -97.08% increase from the -10.39 % ROA in the previous year.

The Helixmith Co ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-10.11 KRW
Jan 1, 2019
-28.82 KRW
Jan 1, 2020
-17.33 KRW
Jan 1, 2021
-18.03 KRW
Jan 1, 2022
-17.14 KRW
Jan 1, 2023
-28.20 KRW
Jan 1, 2024
-10.39 KRW
Jan 1, 2025
-0.30 KRW
The Helixmith Co ROA history
YEARROAYoY
-0.30 %-97.08%
-10.39 %-63.15%
-28.20 %+64.55%
-17.14 %-4.96%
-18.03 %+4.05%
-17.33 %-39.86%
-28.82 %+185.11%
-10.11 %+179.12%
-3.62 %+802.36%
-0.40 %-210.26%
0.36 %+61.48%
0.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

ROA Details

Understanding Helixmith Co's Return on Assets (ROA)

Helixmith Co's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Helixmith Co's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Helixmith Co's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Helixmith Co’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Helixmith Co stock

Return on Assets (ROA) of Helixmith Co is -0.30 % in 2025.

Return on Assets (ROA) of Helixmith Co changed from -10.39 % to -0.30 %, representing a -97.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Helixmith Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Helixmith Co

All Key Metrics — Helixmith Co